The Cooper Companies, Inc.

(NASDAQ Global Select)
Back to all articles
Neutral +10

Boston Trust Walden Corp Has $82.91 Million Holdings in The Cooper ...

AI-generated analysis

πŸ“‰ Boston Trust Walden Corp reduced its COO stake by 6.3% in Q1, selling 77,917 shares while retaining a $82.9 million position.

πŸ“ˆ Smaller funds like Root Financial Partners and True Wealth Design significantly increased their holdings by over 100% and 480% respectively in recent quarters.

🏦 Institutional ownership of The Cooper Companies stands at 24.39% as of the latest SEC filings.

πŸ’° COO trades with a market cap of $14.47 billion and a P/E ratio of 62.88, reflecting high valuation expectations for its medical device segments.

πŸ“Š Analyst consensus is mixed with an average 'Hold' rating and a target price of $81.31, though Wells Fargo has issued a 'sell' rating at $66.

πŸ” Piper Sandler maintains an 'overweight' stance with a $86 price objective, contrasting with JPMorgan's lowered target of $71.

πŸ‘οΈ The company operates two main segments: CooperVision for soft contact lenses and CooperSurgical for women's health products.

πŸ“ˆ Stock technicals show COO trading above its 50-day moving average of $64.36 but below its 200-day average of $73.37.

Bullish Signals
  • Piper Sandler maintains an 'overweight' rating with a specific price objective of $86.00, indicating confidence in the company's growth potential.
  • Wall Street Zen upgraded its rating from 'hold' to 'buy', signaling a positive shift in analyst sentiment regarding the stock.
  • Multiple smaller hedge funds have aggressively increased their stakes, suggesting interest from capital allocators despite the major institutional reduction.
Risk Factors
  • Wells Fargo & Company reissued a 'sell' rating and lowered its price target to $66.00, down from $82.00, highlighting bearish concerns.
  • JPMorgan Chase reduced its price objective from $80.00 to $71.00 and assigned a 'neutral' rating, reflecting caution on the stock's valuation.
  • Robert W. Baird cut its target price from $98.00 to $85.00, indicating a downward revision in expected performance.
Full Analysis
Boston Trust Walden Corp reduced its stake in The Cooper Companies, Inc. (NASDAQ: COO) by 6.3% during the first quarter, selling 77,917 shares to hold a remaining position of 1,159,562 shares valued at approximately $82.9 million. While this major institutional holder decreased its exposure, several smaller hedge funds and investment advisors significantly increased their positions in the fourth or third quarters, with holdings ranging from roughly 300 to 485 shares each. Wall Street analysts have issued mixed signals regarding COO stock following recent performance data. Piper Sandler maintains an 'overweight' rating with a $86 price objective, while Wall Street Zen upgraded the stock to a 'buy.' Conversely, Wells Fargo downgraded the rating to 'sell' with a $66 target, and JPMorgan Chase lowered its price objective to $71, reflecting divergent views on the company's near-term trajectory. The Cooper Companies operates as a global medical device firm headquartered in San Ramon, California, focusing primarily on vision care through CooperVision and women's health via CooperSurgical. Financial metrics show a market capitalization of $14.47 billion with a P/E ratio of 62.88, while the stock trades between its 52-week low of $58.89 and high of $89.83, currently hovering near its 200-day moving average.